Home - Gastroenterology Advisor
WEBGI and Liver Disease in Pregnancy: AGA Clinical Practice Updates. By Colby Stong. The American Gastroenterological Association has released new guidance on the clinical management of pregnancy-related gastrointestinal and liver disease.
Clinician Insights on How to Manage Semaglutide-Induced …
WEBSep 8, 2023 · Patients who receive treatment with a glucagon-like peptide-1 (GLP-1) receptor agonist, such as semaglutide, may experience delayed gastric emptying due to the drug’s mechanism of action (MOA). 1 Symptoms may include nausea, vomiting, heartburn, pain, or bloating. 2 However, the symptoms of delayed gastric emptying resulting from GLP-1 receptor agonists may be similar to symptoms of ...
FDA Alert: Gastroenterology Drug Approvals and New Indications
WEB7 hours ago · FDA New Indications. Voquezna® (vonoprazan): Heartburn Associated With Nonerosive GERD. On July 18, 2024, the FDA approved vonoprazan for the relief of heartburn associated with nonerosive GERD in adults. 5. Medication Class: potassium-competitive acid blocker 6. Dosing: Relief of heartburn with nonerosive GERD in adults: 10 mg once daily for ...
What We Know About Semaglutide Adverse Events and …
WEBSep 1, 2023 · What Are Other Causes of Gastroparesis? Diabetes is the most common underlying cause of gastroparesis and can damage the vagus nerve, leading to impaired muscular function in the stomach and small intestine. 3 Studies show that the 10-year cumulative incidence of diabetic gastroparesis is estimated to be 5.2% among patients with type 1 diabetes and 1% in patients with type 2 diabetes. 4
Weight Reduction Varies for Patients Receiving Semaglutide, …
WEB2 days ago · The researchers found that the mean percentage weight change at one year was –5.1 and –2.2 percent with semaglutide and liraglutide, respectively; –3.2 and –5.9 percent for T2D and obesity as treatment indication; and –5.5, –2.8, and –1.8 percent with persistent medication coverage, with 90 to 275 medication coverage days, and ...
Adiposity Lacks Causal Evidence of Contributing to GI Disease
WEB1 day ago · The umbrella review included 594 observational studies from 23 systematic reviews and meta-analyses and 3 pooled analyses. Within these articles, there were 334 identified associations between adiposity and the risk for GI disease, with a median (range) number of 2137 (23-85,295) cases and 630,056 (163-13,958,940) participants.
2021 American College of Gastroenterology Guidelines: Prevention ...
WEBAug 25, 2021 · The American College of Gastroenterology (ACG) released updated clinical guidelines on the prevention, diagnosis, and treatment of Clostridioides difficile infections (CDI), which was recently published in The American Journal of Gastroenterology.These guidelines represent the official practice recommendations of the ACG and indicate the preferred approach to the management of adults with CDI.
2021 American College of Gastroenterology Guidelines: Upper ...
WEBJun 2, 2021 · The American College of Gastroenterology (ACG) released clinical guidelines on upper gastrointestinal (GI) and ulcer bleeding using an evidence-based approach, which was recently published in The American Journal of Gastroenterology.. The researchers used the Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) methodology to develop 16 clinical recommendations for the ...
Short-Acting GLP-1 RAs May Increase GERD, Barrett Esophagus …
WEBMay 12, 2023. Short-acting GLP-1 receptor agonists are associated with increased risk for GERD and Barrett esophagus among patients with type 2 diabetes. Short-acting glucagon-like peptide 1 (GLP-1) receptor agonists (RAs) are associated with increased risk for developing gastroesophageal reflux disease (GERD) and its associated complications ...
Novel Drug Tradipitant Effective, Safe for Treatment of Nausea in ...
WEBOct 29, 2021 · Tradipitant appears to be an effective and safe treatment option for gastroparesis symptoms, according to research presented at the American College of Gastroenterology (ACG) 2021 Annual Meeting, held from October 22 to 27, 2021, in Las Vegas, Nevada and virtually.
Skip to content